Lipid Disorders
Conference Coverage
Icosapent ethyl cost effective in REDUCE-IT analysis
PHILADELPHIA – Treatment with the fish-derived drug for CV event reduction is more effective and less costly than placebo.
Conference Coverage
Treating LDL to below 70 reduces recurrent stroke
PHILADELPHIA – Results of TST, a rare cholesterol study in patients with a history of ischemic stroke, explore the benefits of treating to a lower...
Conference Coverage
RNA inhibitors silence two new targets in dyslipidemia
PHILADELPHIA –
News from the FDA/CDC
FDA panel supports Vascepa expanded indication for CVD reduction
Icosapent ethyl (Vascepa), purified eicosapentaenoic acid, got unanimous support from an FDA panel for a new indication of reducing CVD events.
From the Journals
Bempedoic acid cuts LDL by 15% in patients already on maximal treatment
CLEAR Wisdom may fill a niche for patients who can’t get levels down.
Latest News
Statins cut long-term CVD risk in kids with familial hypercholesterolemia
There were no cardiovascular-related deaths and one event in treated patients who were followed for 20 years.
Conference Coverage
Low LDL-C and blood pressure can reduce lifetime CVD risk by 80%
PARIS – The effects were seen in those with genetic variants linked with low LDL cholesterol and systolic blood pressure.
Conference Coverage
Closing the missing link between childhood risk factors and adult cardiovascular outcomes
PARIS – Prescient childhood cohort studies launched in the 1970s are paying off.
Conference Coverage
Cancer overtakes CVD as cause of death in high-income countries
PARIS – The balance is shifting because cardiovascular deaths are way down in high-resource nations.
From the Journals
Short-term statin use linked to risk of skin and soft tissue infections
Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days.
Conference Coverage
Smoking, inactivity most powerful post-MI lifestyle risk factors
PARIS –